What Is the First-Line Treatment for Trigeminal Neuralgia?
Clinical Context
Trigeminal neuralgia (ICD-11 8B82.0, ICD-10 G50.0) is addressed through a structured pharmacological protocol. This page outlines the first-line approach and the clinical endpoint used to define successful management.
Treatment Approach
First-line management centres on anticonvulsant medication. The choice between available agents depends on individual patient factors — including potential drug interaction considerations — that are evaluated at the outset. The complete selection criteria, dosing strategy, and monitoring guidance are detailed in the full protocol.
Treatment Goal
Sustained remission — freedom from pain for a defined minimum period — guides decisions on whether to continue, taper, or escalate therapy.
References
- Carbamazepine - therapeutic range is normally between 800mg – 1200mg total daily dose split over 4 separated doses; modified release and liquid forms are also available.
- Recommend HLA-B*1502 allele testing in individuals of Han Chinese or Thai origin (risk of Stevens-Johnson syndrome in presence of HLA-B*1502 allele).
- Oxcarbazepine – alternative should there be medication interaction issues with carbamazepine.
- Therapeutic range is normally between 1200mg – 1800mg total daily dose split over 4 separated doses.
- However, once a remission period is noted i.e. no pain for at least 4 weeks, then the medication can be slowly tapered down and stopped.
View source ↗